[go: up one dir, main page]

AR056712A1 - Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus - Google Patents

Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus

Info

Publication number
AR056712A1
AR056712A1 ARP060104591A ARP060104591A AR056712A1 AR 056712 A1 AR056712 A1 AR 056712A1 AR P060104591 A ARP060104591 A AR P060104591A AR P060104591 A ARP060104591 A AR P060104591A AR 056712 A1 AR056712 A1 AR 056712A1
Authority
AR
Argentina
Prior art keywords
influenza virus
virus
influenza
inoculation
immunogen
Prior art date
Application number
ARP060104591A
Other languages
English (en)
Inventor
Kim Gugisberg
Michael Gill
Hsien-Jue Chu
Yu-Wei Chiang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056712A1 publication Critical patent/AR056712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones, incluyendo vacunas, y métodos para tratar, prevenir o mejorar la enfermedad del virus de la influenza canina (CIV) por medio de utilizar uno o más inmunogenes con cepa de virus de la influenza canina (CIV) o del virus de la influenza equina (EIV). También modelos de inoculacion utiles para determinar la eficacia de una composicion contra el virus de la influenza canina, que comprende una copa del virus de la influenza equina (EIV) o del virus de la influenza canina (CIV) de o inmunogenes de ellos.
ARP060104591A 2005-10-20 2006-10-20 Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus AR056712A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72866205P 2005-10-20 2005-10-20
US73529005P 2005-11-10 2005-11-10

Publications (1)

Publication Number Publication Date
AR056712A1 true AR056712A1 (es) 2007-10-17

Family

ID=37963233

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104591A AR056712A1 (es) 2005-10-20 2006-10-20 Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus

Country Status (5)

Country Link
US (1) US20070092537A1 (es)
EP (1) EP1941033A2 (es)
AR (1) AR056712A1 (es)
TW (1) TW200733972A (es)
WO (1) WO2007047728A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118319960A (zh) * 2024-06-12 2024-07-12 华南农业大学 长效性风寒束肺症疾病动物模型的构建方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CN103451158B (zh) * 2005-04-21 2018-11-23 佛罗里达大学研究基金公司 用于犬科动物中呼吸系统疾病控制的物质和方法
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US20080107687A1 (en) * 2006-11-06 2008-05-08 Herve Poulet Feline vaccines against avian influenza
WO2011112593A1 (en) 2010-03-10 2011-09-15 Intervet International B.V. Method for protecting against disease caused by secondary pathogens
EP2670432B1 (en) * 2011-02-04 2021-03-17 Zoetis Services LLC Immunogenic bordetella bronchiseptica compositions
CN103596588B (zh) * 2011-02-04 2016-02-03 佐蒂斯有限责任公司 用于犬呼吸道疾病综合征的组合物
WO2016083287A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090393A (en) * 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
PT1427444E (pt) * 2001-07-27 2013-11-19 Zoetis W Llc Vacina contra o vírus do nilo ocidental
CN103451158B (zh) * 2005-04-21 2018-11-23 佛罗里达大学研究基金公司 用于犬科动物中呼吸系统疾病控制的物质和方法
US7384642B2 (en) * 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118319960A (zh) * 2024-06-12 2024-07-12 华南农业大学 长效性风寒束肺症疾病动物模型的构建方法

Also Published As

Publication number Publication date
US20070092537A1 (en) 2007-04-26
EP1941033A2 (en) 2008-07-09
WO2007047728A3 (en) 2007-08-02
WO2007047728A2 (en) 2007-04-26
TW200733972A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
CO6160334A2 (es) Metodo para la elaboracion de una vacuna de conbinacion para proteger contra polio
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
MX2009008577A (es) Prevencion y tratamiento contra la enfermedad asociada a arcovirus porcion sub-clinica.
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
IN2012DN02736A (es)
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
AR056712A1 (es) Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
AR047581A1 (es) Vacunas de calicivirus felino
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
TR201820975A2 (tr) İbuprofen, Psödoefedrin ve Erdostein İçeren Uzatılmış Salım Sağlayan Farmasötik Kompozisyon
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
ATE495758T1 (de) Virulentes systemisches felines calicivirus
BR112013023354A2 (pt) vacina para rinite equina
BR112013019850A8 (pt) Composições de vacina e seu uso no tratamento ou prevenção de doenças respiratórias infecciosas caninas
AR054916A1 (es) Vacuna

Legal Events

Date Code Title Description
FB Suspension of granting procedure